Kornimate/medical-research-clean huggingface dataset:
analysis of the incidence and risk factors of chronic pain after cesarean section

Conditions: Postoperative Pain; Cesarean Section Surgery

Summary: persistent postoperative pain is a globally recognized issue that deserves attention. cesarean section is one of the surgeries that may cause persistent postoperative pain. pspp may affect communication between mother and baby, and may lead to postpartum depression, which has a negative impact on the daily activities and quality of life of mothers. it is an important clinical issue. the main purpose of this study is to (1) prospectively investigate the overall incidence and characteristics of persistent pain after cesarean section at 3, 6, and 12 months after surgery; (2) use regression analysis and data modeling analysis to evaluate the relationship between perioperative variables and chronic pain in postpartum women undergoing cesarean section; (3) analyze the relationship between chronic pain after cesarean section and postpartum depression in postpartum women.


Eligibility criteria:
inclusion criteria: * age range from 20 to 50 years old; * asa grades i to iii; * full term pregnancy and planned cesarean section with transverse incision in the lower segment of the uterus; * pregnant women who are willing to participate in this study and sign informed consent forms. exclusion criteria: * have a history of dementia, mental illness, or any central nervous system disorder; * pregnant women who are addicted to alcohol and drugs; * difficulty in follow-up or poor patient compliance; * has taken other investigational drugs or participated in other clinical trials in the three months prior to being selected for the study; * serious complications occur during delivery; * unable to cooperate with the research for any reason.

Keywords: postoperative pain chronic postoperative pain cesarean section surgery postpartum depression
rehabilitating overweight people back to working life

Conditions: Obesity

Summary: obesity may have implications on the individual's participation in working life through different mechanisms such as comorbidity and loss of functional level. the investigators also know that when exiting the working force, it is difficult to get back later. as rehabilitation back to working life is often not a very focused aim with weight loss treatment, this study sets this as a primary aim by involvement in a 4 week stay at a rehabilitation clinic followed by 48 weeks work practice programme at one of three different companies.


Eligibility criteria:
inclusion criteria: * bmi 30-47 * 19-67 years exclusion criteria: * pregnancy * significant reduced physical function * drug use * serious mental illness
glucose/insulin clamp on solid organ transplant (liver, kidney, pancreas and heart) on cadaveric donors

Conditions: Complication of Transplanted Organ, Nos

Summary: our objective in this study will be to determine if implementing the glucose/insulin clamp (gict) on cadaveric organ donors can: * prevent hyperglycaemia * drop in the inflammatory cytokine response after brain death after a minimum of 6 hours therapy with the gict prior to organ procurement. * assess organ (heart, liver, pancreas and kidney) survival at one year post-transplant * assess graft function by evaluating: * liver: post-transplant liver function score (ptlf) * kidney: graft function as defined by unos (immediate graft function igf, slow graft function sgf and delayed graft function dgf and * pancreas: 7 day post-transplant insulin requirement, c-peptide and c-rp levels at day one and seven post-transplantation


Eligibility criteria:
inclusion criteria: * donors must be over 18 years of age * brain death donors only * getting consent prior to any specific protocol procedure under transplant quebec regulations. exclusion criteria: * inability to obtain a research consent * time interval between the start of the study and cross-clamping less than 6 hours. * no solid organs retrieved for transplantation * diagnosed with type 1 diabetes * donor has uncontrolled serum blood glucose levels (above 10 mmol/l) at time of inclusion

Keywords: inflammatory process hyperglycaemia inflammatory cytokine response organ survival hyperinsulinemic clamp
influence of tyg index and tg/hdl-c ratio on fetal macrosomia

Conditions: Fetal Macrosomatia; Lipid Metabolism Disorders; Hyperlipidemias

Summary: metabolic disorders that can occur during pregnancy, in particular disorders of lipid metabolism and insulin resistance, can have a detrimental effect on pregnancy and the fetus. the triglyceride level and other lipids increase slightly during pregnancy. this increase has a positive effect on the development of the fetus. however, an excessive increase in lipid levels can cause some metabolic disorders such as gestational diabetes and increase feto-maternal morbidity/mortality. while some existing studies have shown that elevated triglyceride levels can cause fetal macrosomia, others have found no correlation between these two variables. the ratio of triglycerides to hdl is a widely used marker for lipid disorders. in addition, the triglyceride-glucose index is also an index used to detect insulin resistance.

in this study, the investigators aimed to investigate whether the ratio of triglycerides to high-density lipoprotein cholesterol and the triglyceride glucose index are associated with fetal macrosomia in low-risk nulliparous pregnant women.

Eligibility criteria:
inclusion criteria: * screening for fetal macrosomia was based on the term defined according to the standards of the american college of obstetricians and gynecologists (acog). * low-risk nulliparous singleton pregnant women. * age between 18 and 40 years old exclusion criteria: * post-term pregnancies * hospitalized for preterm labor or preterm premature rupture of membranes. * gestational diabetes mellitus, diabetes mellitus type i - type ii. * pregnant women with fetal growth restriction, hypertensive pregnancy disorders, familial hypercholesterolemia and hyperlipidemia. * multiparous pregnant women * multiple pregnancies * pregnant women with chronic diseases. * pregnant women with impaired liver function; * pregnant women with body mass index \ 40 kg/m2.

Keywords: fetal macrosomia nulliparous triglyceride tyg index
real-time interactive digital healthcare system in post operation patients with breast cancer; pilot study

Conditions: Breast Cancer; Rehabilitation

Summary: this study aims to examine the effect of hospital-home linkage short-term rehabilitation therapy using real-time interactive digital healthcare system (uincare homeplus) in post-operative patients with breast cancer. this is prospective pilot study. 20 breast cancer patients who underwent wide local excision-axillary lymph node diessection or modified radical mastectomy will be examined, and those with limited range of motion (rom) of affected shoulder will be enrolled in the study. shoulder rom, quick-dash, pain evaluation with nrs, quality of life evaluation with fact-b and eq-5d will be evaluated on enrollment, 4-week, 8-week, and 12-weeks after enrollment.

the limited range of motion (rom) of the shoulder occur often after receiving breast cancer surgery, which may be due to post-operative pain, stiffness of shoulder girdle muscle, and etc. due to this limited rom, the patients may suffer difficulty in activities of daily life and quality of life may be reduced. uincare homeplus is software manufactured in korea, which uses infrared, kinect camera and motion capture technology to track 3d motion of the patients' articulation. using this technology, the patients can receive feedback of their motion immediately. the objective of the study is to examine the effect of hospital-home linkage short-term rehabilitation therapy using real-time interactive digital healthcare system (uincare homeplus) in post-operative patients with breast cancer.

Eligibility criteria:
inclusion criteria: * patients who underwent breast cancer surgery (wide local excision-axillary lymph node dissection or modified radical mastectomy) * limited active/passive range of motion of the affected shoulder (flexion \<160' or abduction \<160') * post-operative day not exceeding 8 week * patients who agreed informed consent exclusion criteria: * bilateral breast cancer surgery * patients with shoulder pain of limited rom before breast cancer surgery * those unable to perform exercise due to general deconditioning * those with communication difficulty
assessment of gastric motility on funtional dyspepsia and joint hypermobility syndrome

Conditions: Functional Dyspepsia; Joint Hypermobility Syndrome

Summary: functional dyspepsia (fd) is defined as the presence of gastroduodenal symptoms in the absence of organic disease that is likely to explain the symptoms. joint hypermobility (jh) refers to the increased passive or active movement of a joint beyond its normal range. recent reports have highlighted the co-existence of fd with ehlers-danlos syndrome type iii or hypermobility type (edsiii). the association between fd and eds iii, and the underlying pathophysiological alterations, are poorly understood. we hypothesised that eds iii might influence gastroduodenal sensorimotor function, resulting in dyspeptic symptoms. therefore, the aim of this study is to explore the impact of eds iii on gastric motility, nutrient tolerance and dyspeptic symptoms in patients with functional dyspepsia.our aim is to study the prevalence of edsiii in fd compared to healthy subjects (hs) and to study the impact of co-existing edsiii on gastric motility, nutrient tolerance and dyspeptic symptoms in fd.


Eligibility criteria:
inclusion criteria: - patients with pds diagnosis as per rome iii by rome iii questionnaire exclusion criteria: patients are excluded from the study if any of the following criteria are met: * females who are pregnant or lactating. * patients who are h. pylori positive * patients with confirmed gastro-intestinal disease, with former digestive surgery affecting upper gut motility, a concomitant disease responsible for digestive symptoms * patients presenting with predominant symptoms of irritable bowel syndrome (ibs), cin or gerd.
first clinical evaluation of a novel glucose non-invasive sensor technology in patients with type 1 diabetes

Conditions: Diabetes Mellitus

Summary: the primary aim of this clinical study is to find signal characteristics of vocs detected by sokru device during fasting, insulin injection and after glucose intake and to find the association with blood glucose variation in variant states of glycemia and hypoglycemia.


Eligibility criteria:
inclusion criteria: * written informed consent * t1d with mdi or csii therapy \>1 year * age 18 - 50 (inclusive) * caucasian ethnicity * bmi between 18.5 and 24.9 kg/m2 (inclusive) * usage of a continuous glucose monitoring (cgm) exclusion criteria: * pregnancy or breastfeeding * history of cardiovascular diseases * diabetes-related comorbidities * hba1c \>9 % * epilepsy * known sensitivity to medical grade adhesives or other skin-related complications, which might influence the outcome * known sensitivity to latex * participation in another investigation with an investigational drug within the 30 days preceding and during the present investigation

Keywords: volatile organic compounds hypoglycaemia
drug interactions between echinacea purpurea and darunavir/ritonavir

Conditions: HIV Infections

Summary: the purpose of this clinical trial is to characterize drug interactions between one medicinal herb widely used by hiv infected patients: echinacea sp. and the protease inhibitor darunavir/ritonavir.

15 patients on antiretroviral therapy with darunavir/ritonavir 600/100 mg twice a day during four weeks will be recruited. the patients will receive treatment with echinacea purpurea for 14 days, 500 mg every 6 hours. a 12 hour pharmacokinetic curve will be obtained at baseline and on day 14.

Eligibility criteria:
inclusion criteria: 1. patients infected with hiv-1 (at least one documented positive western-blot). 2. age =/+ 18 years. 3. patients receiving antiretroviral therapy containing darunavir / ritonavir at the approved dose of 600/100 mg twice daily for at least 4 weeks 4. hiv viral load in plasma \<50 copies / ml 5. absence of acute infections and / or tumors in the three months prior to inclusion. 6. subject able to follow the treatment period, without suspicion of poor adherence in previous antiretroviral treatments. 7. voluntary written informed consent. exclusion criteria: 1. any clinical or historical observation that could interfere with the pharmacokinetics of medications, such as gastrointestinal illness or surgery (except for herniotomy and appendectomy), changes in the composition of plasma proteins, some indication of hepatic or renal dysfunction. 2. active alcohol consumption (\> 50 g / day) or illicit drugs (except cannabis). 3. pregnancy or lactation

Keywords: darunavir echinacea purpurea interaction complementary therapies
a study of il4rα monoclonal antibody in patients with uncontrolled seasonal allergic rhinitis.

Conditions: Allergic Rhinitis

Summary: allergic rhinitis (ar) is a non-infectious chronic inflammatory disease of the nasal mucosa mainly mediated by immunoglobulin e after exposure to allergens in atopic individuals. the typical symptoms of ar are paroxysmal sneezing, watery rhinorrhea, itching, and nasal congestion, which may be accompanied by ocular symptoms, including eye itching, tearing, redness, and burning sensation, which are more common in patients with hay fever allergies. bronchial asthma is associated with bronchial asthma in 40% of patients with ar, suggesting a comorbid feature of allergic disease.


Eligibility criteria:
key inclusion criteria: 1. subjects meet the diagnosis of sar which has been prevalent for at least 2 years, and: standard treatment regimen for sar was ineffective or subjective symptom control was unsatisfactory in the subject; positive test for at least one allergen associated with the development of sar; pre-baseline symptom episodes of ≥ 4 days/week and a baseline tnss of ≥ 6 points. 2. consent to highly effective contraception key exclusion criteria: 1. other nasal comorbidities or co-morbidities/states that may be present at the time of screening； 2. it is expected that subjects' exposure to allergens in their home or work environments may change significantly during the study period. 3. patients with asthma requiring stable use of inhaled controlled medications; 4. previous or current malignant tumor within 5 years prior to screening; 5. presence of other acute or chronic diseases or abnormal laboratory tests at the time of screening that, in the investigator's assessment, may have a more serious impact on the efficacy or safety assessment of the subject; 6. live/live attenuated vaccine within 3 months prior to baseline; 7. subjects with very limited outdoor activity during the daytime, as inferred from their regular daily routine; 8. unwillingness or inability to comply with the permitted and prohibited medication/treatment specifications of the study, inability to meet the pre-randomization drug elution cycle specified in the protocol; 9. women who are pregnant or breastfeeding; 10. history of alcohol or drug abuse within 3 months prior to screening.
hmf preterm case studies

Conditions: Preterm Infants

Summary: nutritional requirements in preterm infants can be elevated, as a result of complex clinical circumstances including infections, immaturity of the gastrointestinal tract and invasive treatments, such as surgery which can place a greater metabolic demand on the body. furthermore, these circumstances can impact an infant's ability to meet nutritional requirements and achieve optimum growth through normal feeding alone. most preterm infants may need specialist care by the neonatal team during hospital admission and post-discharge, which includes enteral nutritional support. human milk fortifier (hmf) have become a component of the routine clinical care of preterm infants on neonatal units. there is published evidence to support this practice as being safe and effective. a multitude of trials have demonstrated improvements in weight, length and head circumference following interventions using hmf, compared to non-supplemented cohorts, and benefits have been observed at long term follow up. whilst hmf is used routinely in neonatal units, there is little clinical evidence for using them beyond discharge in the community, although this is widely accepted in practice. nutricia have developed a new hmf (nhmf) that can be provided for use in the community. this series of case-studies will evaluate the tolerance, compliance, acceptability and safety of the nhmf, in 15 preterm infants. each case study will last at least 28 days, including at least 7 days in the community setting. the case studies will be conducted across multiple specialist neonatal centres in the uk, to meet the uk acbs requirements.


Eligibility criteria:
inclusion criteria: * preterm infants fed own mother's milk (or donor human milk) requiring hmf (as decided by the investigator) * born before 37 weeks completed gestational age and \>1 dropped centile since birth requiring hmf (as decided by the investigator) * tolerating adequate volume of enteral nutrition * expected to require hmf after discharge (minimum 4.0g nhmf per day at discharge) * written or electronic informed consent from parent/caregiver exclusion criteria: * anticipated short term use of hmf leading to discontinuation of hmf after hospital discharge * presence of any relevant proven or suspected chromosomal anomaly or genetic syndrome, any gastrointestinal malformation/compromise, including necrotising enterocolitis (nec) (defined as bell's stage two or higher), metabolic disorder, or congenital central nervous system malformation that may impact tolerance of enteral feeding * failure to establish enteral nutrition and requiring full parenteral nutrition * participation in other studies within 1 month prior to the entry of this study * known allergy to any of the study product ingredients, including cow's milk, fish and egg * concern or issues around the breast milk supply from mother of preterm infant at enrolment * investigator concerns around willingness/ability of the parent/caregiver to comply with protocol requirements and/or handle and store nhmf appropriately
text4vax: text message reminders for pediatric covid-19 and influenza vaccines 2024-25 season

Conditions: Influenza; COVID-19; Vaccination Hesitancy

Summary: this multi-site study assesses the impact of text message reminders on the receipt of covid-19 and influenza text message reminders takes place primarily in practices from the american academy of pediatrics (aap) pediatric research in office settings (pros) network.

the study is to be conducted over the 1st season (september 2024-april 2025) as an effectiveness trial and the 2nd (september 2025-april 2026) as a replication study. this protocol covers the first season. parents of eligible children who are 6 month-17 year-old who are due for both a covid-19 and influenza vaccine will be sent text messages. within each practice site, parents of eligible children will be randomized to receive either: 1) combined covid-19 and influenza vaccine text message reminders, 2) covid-19 reminders alone, 3) influenza reminders alone, or 4) no reminders (usual care). randomization is to be stratified by practice site, age group and prior year's covid-19/influenza vaccine history. messages will be sent centrally and managed by the research team.

Eligibility criteria:
inclusion criteria: * child that: * is 6 months-17 year-old children * due for both a covid-19 and influenza vaccine * receives care at study site * language listed in electronic health record is english or spanish * has not opted out of text messages from practice exclusion criteria: * has opted out of text messages from practice * language listed in electronic health record is not english or spanish

Keywords: text message short message service (sms) mhealth
cognitive behavioral therapy and real-time self-management intervention for scd via mobile applications

Conditions: Sickle Cell Disease; Depression; Anxiety

Summary: patients with sickle cell disease (scd) experience significant depressive symptoms that currently go unrecognized and under-treated. further, depression in this patient population has the potential to contribute to high health care utilization and poor disease outcomes; however, there are currently no comparative effectiveness studies of evidenced-based mental health treatments for depression in scd. the primary objective of this study is to test the effectiveness of an online computerized cognitive behavioral therapy intervention to address psychological and behavioral needs of patients with sickle cell disease, namely depression and pain symptoms. the investigators will implement an existing computerized cognitive behavioral therapy (ccbt) program called "beating the blues" into routine clinical care at the university of pittsburgh medical center (upmc) adult sickle cell clinic to determine the effectiveness of this intervention in decreasing depression and pain versus treatment as usual. patients with significant distress-depression and/or anxiety symptoms-will be randomized to either eight sessions of a ccbt program and weekly follow-up with a care manager or treatment as usual where the treating physician is notified of the patient's symptoms. the investigators will evaluate patient acceptability, implementation and practicality of the online mental health intervention through patient use of the site (frequency and duration of visits), qualitative interviews, and surveys. the investigators hypothesize: 1) the ccbt will be an acceptable mental health treatment for patients and easily integrated into routine clinical care; 2) patients in the treatment arm will show a greater decrease in depression/anxiety symptoms and average daily pain than patients in usual care.


Eligibility criteria:
inclusion criteria: 1. male or female ≥18 years of age at baseline visit. 2. documentation of a scd diagnosis (hgbss, hgbsc, sbeta +thal; or sbeta othal) 3. receive routine care at the upmc sickle cell clinic. 4. scores indicative of clinically significant depression or anxiety on the stress/pain screener that is administered as part of routine scd care to all patients. i.e. patient health questionnaire (phq-9) ≥ 10 and/or generalized anxiety disorder scale (gad-7) ≥ 8 exclusion criteria: 1. presence of a condition or abnormality (e.g. significant neurocognitive dysfunction) that in the opinion of the investigator would compromise the safety of the patient or the quality of the data.
the role of subscapularis repair in reverse shoulder arthroplasty

Conditions: Arthropathy Shoulder

Summary: the overall goal of the study is to determine if repairing the subscapularis tendon during primary reverse shoulder arthroplasty effects short-term patient outcomes. the study is a patient blinded randomized controlled trial that is currently enrolling.


Eligibility criteria:
inclusion criteria: * adults undergoing primary reverse shoulder arthroplasty exclusion criteria: * adults without an intact subscapularis * inflammatory arthritis * revision surgery